全文获取类型
收费全文 | 6584篇 |
免费 | 460篇 |
出版年
2024年 | 8篇 |
2023年 | 38篇 |
2022年 | 59篇 |
2021年 | 203篇 |
2020年 | 118篇 |
2019年 | 155篇 |
2018年 | 181篇 |
2017年 | 147篇 |
2016年 | 260篇 |
2015年 | 379篇 |
2014年 | 406篇 |
2013年 | 493篇 |
2012年 | 563篇 |
2011年 | 518篇 |
2010年 | 352篇 |
2009年 | 329篇 |
2008年 | 395篇 |
2007年 | 410篇 |
2006年 | 305篇 |
2005年 | 277篇 |
2004年 | 290篇 |
2003年 | 248篇 |
2002年 | 250篇 |
2001年 | 83篇 |
2000年 | 46篇 |
1999年 | 57篇 |
1998年 | 72篇 |
1997年 | 59篇 |
1996年 | 28篇 |
1995年 | 31篇 |
1994年 | 37篇 |
1993年 | 22篇 |
1992年 | 30篇 |
1991年 | 24篇 |
1990年 | 19篇 |
1989年 | 15篇 |
1988年 | 15篇 |
1987年 | 8篇 |
1986年 | 8篇 |
1985年 | 14篇 |
1984年 | 16篇 |
1983年 | 17篇 |
1982年 | 15篇 |
1981年 | 7篇 |
1980年 | 7篇 |
1979年 | 4篇 |
1978年 | 5篇 |
1977年 | 3篇 |
1974年 | 5篇 |
1973年 | 4篇 |
排序方式: 共有7044条查询结果,搜索用时 109 毫秒
991.
992.
Yan-Guo Ren Javier Martínez Anders Virtanen 《The Journal of biological chemistry》2002,277(8):5982-5987
Poly(A)-specific ribonuclease (PARN) is the only mammalian exoribonuclease characterized thus far with high specificity for degrading the mRNA poly(A) tail. PARN belongs to the RNase D family of nucleases, a family characterized by the presence of four conserved acidic amino acid residues. Here, we show by site-directed mutagenesis that these residues of human PARN, i.e. Asp(28), Glu(30), Asp(292), and Asp(382), are essential for catalysis but are not required for stabilization of the PARN x RNA substrate complex. We have used iron(II)-induced hydroxyl radical cleavage to map Fe(2+) binding sites in PARN. Two Fe(2+) binding sites were identified, and three of the conserved acidic amino acid residues were important for Fe(2+) binding at these sites. Furthermore, we show that the apparent dissociation constant ((app)K(d)) values for Fe(2+) binding at both sites were affected in PARN polypeptides in which the conserved acidic amino acid residues were substituted to alanine. This suggests that these residues coordinate divalent metal ions. We conclude that the four conserved acidic amino acids are essential residues of the PARN active site and that the active site of PARN functionally and structurally resembles the active site for 3'-exonuclease domain of Escherichia coli DNA polymerase I. 相似文献
993.
994.
995.
Javier Delgado Blanco Xavier Hernandez-Alias Damiano Cianferoni Luis Serrano 《PLoS computational biology》2020,16(12)
The coronavirus disease COVID-19 constitutes the most severe pandemic of the last decades having caused more than 1 million deaths worldwide. The SARS-CoV-2 virus recognizes the angiotensin converting enzyme 2 (ACE2) on the surface of human cells through its spike protein. It has been reported that the coronavirus can mildly infect cats, and ferrets, and perhaps dogs while not pigs, mice, chicken and ducks. Differences in viral infectivity among different species or individuals could be due to amino acid differences at key positions of the host proteins that interact with the virus, the immune response, expression levels of host proteins and translation efficiency of the viral proteins among other factors. Here, first we have addressed the importance that sequence variants of different animal species, human individuals and virus isolates have on the interaction between the RBD domain of the SARS-CoV-2 spike S protein and human angiotensin converting enzyme 2 (ACE2). Second, we have looked at viral translation efficiency by using the tRNA adaptation index. We find that integration of both interaction energy with ACE2 and translational efficiency explains animal infectivity. Humans are the top species in which SARS-CoV-2 is both efficiently translated as well as optimally interacting with ACE2. We have found some viral mutations that increase affinity for hACE and some hACE2 variants affecting ACE2 stability and virus binding. These variants suggest that different sensitivities to coronavirus infection in humans could arise in some cases from allelic variability affecting ACE2 stability and virus binding. 相似文献
996.
Javier Rasero Amy Isabella Sentis Fang-Cheng Yeh Timothy Verstynen 《PLoS computational biology》2021,17(3)
Variation in cognitive ability arises from subtle differences in underlying neural architecture. Understanding and predicting individual variability in cognition from the differences in brain networks requires harnessing the unique variance captured by different neuroimaging modalities. Here we adopted a multi-level machine learning approach that combines diffusion, functional, and structural MRI data from the Human Connectome Project (N = 1050) to provide unitary prediction models of various cognitive abilities: global cognitive function, fluid intelligence, crystallized intelligence, impulsivity, spatial orientation, verbal episodic memory and sustained attention. Out-of-sample predictions of each cognitive score were first generated using a sparsity-constrained principal component regression on individual neuroimaging modalities. These individual predictions were then aggregated and submitted to a LASSO estimator that removed redundant variability across channels. This stacked prediction led to a significant improvement in accuracy, relative to the best single modality predictions (approximately 1% to more than 3% boost in variance explained), across a majority of the cognitive abilities tested. Further analysis found that diffusion and brain surface properties contribute the most to the predictive power. Our findings establish a lower bound to predict individual differences in cognition using multiple neuroimaging measures of brain architecture, both structural and functional, quantify the relative predictive power of the different imaging modalities, and reveal how each modality provides unique and complementary information about individual differences in cognitive function. 相似文献
997.
Gabriele Murineddu Francesco Deligia Giulio Ragusa Laura García-Toscano María Gómez-Cañas Battistina Asproni Valentina Satta Elena Cichero Ruth Pazos Paola Fossa Giovanni Loriga Javier Fernández-Ruiz Gerard A. Pinna 《Bioorganic & medicinal chemistry》2018,26(1):295-307
A series of sulfenamide and sulfonamide derivatives was synthesized and evaluated for the affinity at CB1 and CB2 receptors. The N-bornyl-S-(5,6-di-p-tolylpyridazin-3-yl)-sulfenamide, compound 11, displayed good affinity and high selectivity for CB1 receptors (Ki values of 44.6?nM for CB1 receptors and >40?μM for CB2 receptors, respectively). The N-isopinocampheyl-sulfenamide 12 and its sulfonamide analogue 22 showed similar selectivity for CB1 receptors with Ki values of 75.5 and 73.2?nM, respectively. These novel compounds behave as antagonists/inverse agonists at CB1 receptor in the [35S]-GTPγS binding assays, and none showed adequate predictive blood–brain barrier permeation, exhibiting low estimated LD50. However, testing compound 12 in a supraspinal analgesic test (hot-plate) revealed that it was as effective as the classic CB1 receptor antagonist rimonabant, in reversing the analgesic effect of a cannabinoid agonist. 相似文献
998.
Macrolide use in the previous years is associated with failure to eradicate Helicobacter pylori with clarithromycin‐containing regimens 下载免费PDF全文
Pablo Muñoz‐Gómez Junior Alexander Jordán‐Castro María Abanades‐Tercero José Javier Blanco‐González Eva María Andrés Esteban Julio Valle‐Muñoz 《Helicobacter》2018,23(1)
Background
There is some evidence that prior use of macrolide antibiotics is a useful predictor of the likelihood of standard triple therapy failure in Helicobacter pylori eradication. In this study, we have evaluated whether previous intake of macrolides correlates with failure to eradicate H. pylori using two different first‐line clarithromycin‐containing regimens.Materials and Methods
Retrospective study of 212 patients with H. pylori infection treated with one of two first‐line clarithromycin‐containing regimens: 108 patients treated with triple therapy for 10 days and 104 patients treated with concomitant therapy for 10 days. The intake of macrolides (clarithromycin, azithromycin, and other macrolides) prior to the eradication therapy was obtained from the electronic medical record, which contains information regarding all the medication prescribed to the patients since the year 2004.Results
One hundred of 212 patients (47.2%) had received at least one treatment with macrolides during the years prior to the eradication therapy. H. pylori eradication rates were significantly lower in patients with previous use compared to patients without previous use of macrolides, both with triple therapy (60.8% vs 92.9%; P < .0001) and with concomitant therapy (85.7% vs 98.2%; P = .024).Conclusions
Previous use of macrolides correlates with a low H. pylori eradication rate with triple and concomitant clarithromycin‐containing regimens. In addition, our study shows that in patients without previous use of macrolides, triple therapy achieves per‐protocol eradication rates over 90%. 相似文献999.
Mengsheng Gao Anne Benge Julia M. Mesa Regina Javier Feng-Xia Liu 《Biological procedures online》2018,20(1):8